Clinical Trials Arena on MSN
ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles
Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.
Of 140 patients enrolled, 48.6% had stage IVM1b/c/d disease, 65.7% had primary anti–PD-1 resistance, 56.4% were PD-L1 negative, and 46.4% received prior anti–PD-1 and anti–cytotoxic T-lymphocyte ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback